Plain-English translation of NCT05833321 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Ovarian Neoplasms research guide →This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This research study is looking for the best ways to detect sarcopenia—significant loss of muscle mass and strength—in people with ovarian or endometrial cancer who are starting chemotherapy. Researchers will use several simple tests, including hand grip strength measurements, walking speed tests, and body composition scans, to understand which methods work best for identifying muscle loss in cancer patients.
Muscle loss is common in cancer patients and can affect how well they tolerate chemotherapy and how they recover. Right now, doctors don't have a standard, simple way to detect it in everyday practice. This study aims to create an easy screening method that could help doctors catch and address muscle loss early.
You likely qualify if…
You likely don't qualify if…
You would visit the hospital for several assessments, which may include a hand grip strength test, a timed walking test, body composition measurements, and questions about your nutrition and food intake. You would also have standard blood tests and possibly a CT scan (if one is already part of your cancer care). The study takes place at one hospital in France and involves a single evaluation period before you start chemotherapy.
AI-generated summary from trial data · Jul 18, 2026 · Not medical advice
France